Protalix Biother SEC Filings

Forster Eliot, a director of Protalix BioTherapeutics, Inc. (PLX), reported transactions on 09/03/2025 showing an acquisition of equity awards. The filing discloses 7,500 restricted shares of common stock awarded under the companys amended 2006 Stock Incentive Plan, held indirectly through a trust and vesting in 12 equal quarterly installments commencing on the grant date. The reporting person also received 15,000 stock options with a $1.64 exercise price that were granted the same date; those options vest in 12 equal quarterly installments and expire on 09/03/2035. The Form 4 also notes existing options to buy 85,715 shares at $1.75 expiring 09/14/2033. The document is signed by an attorney-in-fact on 09/04/2025.

Protalix BioTherapeutics insider grant and option award reported. Director Gwen A. Melincoff was awarded 7,500 restricted shares of common stock on 09/03/2025 under the company’s Amended and Restated 2006 Stock Incentive Plan; the restricted shares vest in 12 equal quarterly installments and are registered in the name of a trustee to qualify for Israeli tax benefits. On the same date she was granted 15,000 stock options with an exercise price of $1.64 that expire on 09/03/2035; the option shares vest in 12 equal quarterly installments. The reporting person’s indirect ownership following the restricted-share grant is 7,500 shares, and 15,000 underlying shares are held directly via the option grant.

Reporting person: Pol F. Boudes, a director of Protalix BioTherapeutics, Inc. (PLX). Transaction date: 09/03/2025.

The Form 4 discloses that the reporting person was awarded 7,500 restricted shares of common stock under the companys 2006 Stock Incentive Plan, held indirectly by a trustee to qualify for Israeli tax treatment, with the restricted shares vesting in 12 equal quarterly installments. The filing also shows the acquisition of 15,000 stock options with an exercise price of $1.64, granted 09/03/2025, exercisable through 09/03/2035, with the underlying shares vesting in 12 equal quarterly installments. The Form notes additional outstanding option grants held by the reporting person that are not part of this grant.

Director Christian Elze acquired equity in Protalix BioTherapeutics (PLX) on 09/03/2025. The Form 4 reports an acquisition of 7,500 restricted shares of common stock that are registered in the name of a trustee to qualify for Israeli tax treatment, with the restricted shares vesting in 12 equal quarterly installments beginning on the grant date. The filing also shows an award of stock options to purchase 15,000 shares at an exercise price of $1.64, exercisable through 09/03/2035, with the options vesting in 12 equal quarterly installments commencing on the grant date. Following the reported transactions, the reporting person beneficially owns 7,500 common shares (indirect) and 15,000 options (direct).

Aharon Schwartz, a director of Protalix BioTherapeutics, Inc. (PLX), reported equity awards and option grants on 09/03/2025. He was awarded 7,500 restricted shares of common stock that vest in 12 equal quarterly installments and are held indirectly by a trust to qualify for Israeli tax benefits. He disposed of 303,000 shares on the same date. He was also granted stock options to buy 15,000 shares at a $1.64 exercise price, exercisable beginning 09/03/2025 and expiring 09/03/2035, with the underlying shares vesting in 12 equal quarterly installments. The reporting notes additional outstanding options totaling 151,676 shares across prior grants at various exercise prices and expirations.

Protalix BioTherapeutics (PLX) director Ben Zvi Shmuel received equity awards on 09/03/2025. The filing reports 7,500 restricted shares granted under the companys amended 2006 Stock Incentive Plan, held indirectly by trust to qualify for Israeli Section 102 tax benefits, and 15,000 stock options with a $1.64 exercise price that expire on 09/03/2035. The restricted shares and options each vest in 12 equal quarterly installments commencing on the grant date. The filing also discloses additional outstanding options with various exercise prices and expiration dates.

Bar-Shalev Amos, a director of Protalix BioTherapeutics, Inc. (PLX), reported transactions on 09/03/2025. He was awarded 7,500 restricted shares under the companys Amended and Restated 2006 Stock Incentive Plan; those shares are registered in a trustee to meet Israeli Section 102 requirements and vest in 12 equal quarterly installments, with accelerated vesting on a corporate transaction or change in control. He also received a grant of 15,000 stock options with a $1.64 exercise price exercisable from 09/03/2025 and expiring 09/03/2035. Following the transactions the reporting person beneficially owns 7,500 shares indirectly and directly holds 15,000 option-based shares. The Form notes a separate disposition of 168 shares. The filing was signed by an attorney-in-fact on 09/04/2025.

Naos Yaron, Sr. VP, Operations of Protalix BioTherapeutics (PLX), reported transactions dated 09/03/2025. He was awarded 25,000 restricted shares under the company's Amended and Restated 2006 Stock Incentive Plan, which vest in 12 equal quarterly installments and accelerate on a corporate transaction or change in control. The shares are registered in the name of a trustee to comply with Israeli tax rules.

On the same date he was granted a stock option to buy 50,000 shares at $1.64 per share exercisable through 09/03/2035 with a similar 12-quarter vesting schedule. The Form 4 also reports a sale of 7,112 shares and shows 225,817 shares beneficially owned following the transactions (held indirectly by a trust).

Protalix BioTherapeutics (PLX) reporting person Dror Bashan, who is President, CEO and a director, recorded equity awards and a disposition on 09/03/2025. He was granted 195,000 restricted shares under the company’s amended 2006 Stock Incentive Plan that vest in 12 equal quarterly installments and are registered in a trustee for Israeli tax purposes. The filing also shows a grant of a stock option covering 340,000 shares with a $1.64 exercise price, exercisable immediately and expiring 09/03/2035, and a reported disposition of 132,516 common shares. The restricted shares and options include accelerated vesting on a corporate transaction or change in control as described in the Plan.